Business UpdateApr 27, 2026, 04:43 PM
CLLS Presents Epigenetic Editing Platform at ASGCT; >90% Gene Reduction
AI Summary
Cellectis presented new research on a TALE-based epigenetic editing platform at the American Society of Gene and Cell Therapy (ASGCT) annual meeting. This innovative approach can turn genes off without altering the DNA sequence, positioning it as a potentially safer alternative for genome editing. The company developed a high-throughput screening system and demonstrated over 90% reduction in gene activity for target genes in both liver cells and T-cells, with sustained results throughout the study. This advancement significantly enriches Cellectis' gene-editing capabilities.
Key Highlights
- Cellectis presented TALE-based epigenetic editing platform at ASGCT annual meeting.
- Platform turns genes off without altering DNA, offering a potentially safer alternative.
- Developed a high-throughput screening system for TALEMs.
- Achieved >90% reduction in gene activity for target genes in hepatocytes and T-cells.
- Gene activity reduction remained stable throughout the study.
- Enriches Cellectis' gene-editing toolbox.